Mecanismos moleculares que regulan la expresión de SHBG: implicaciones en la obesidad

Cristina Sáez López

Dr. David Martínez Selva Dra. Cristina Hernández Pascual Dr. Rafael Simó Canonge

Laboratorio de Diabetes y Metabolismo

The work focuses on resolving the clinical problems produced by these pathological situations, with big impact in our society. Obesity has long been associated with these serious health issues, although it has only recently been regarded as a disease in the sense of being a specific target for medical therapy. Developing obesity treatments that target novel pathways is a growing focus for both biopharmaceutical and the medical device industries, because until now there does not exists any secure and effective treatment.

Estos resultados tienen un claro potencial de aplicación en la industria farmacéutica, ya que sientan las bases para el uso de la SHBG como terapia contra la obesidad y sus comorbilidades, como la esteatosis hepática. Por ello, hemos solicitado la patente europea «Uso de la SHBG como medicamento» (EP13382202.3), con fecha de prioridad el 30/05/2013. Actualmente, buscamos socios en la industria para licenciar esta patente y colaborar en el desarrollo completo de esta posible aplicación.

Pharma Industry; Potential Application; SHBG; Therapy; Obesity; Related Comorbidities; Hepatic Steatosis; European Patent; Use of SHBG as a Medicament; EP13382202.3; Priority Date; Partners; License Patent; Collaboration; Develop Potential Application